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Hepcidin in Human Iron Disorders:
Diagnostic Implications
Joyce J.C. Kroot,1 Harold Tjalsma,1,2 Robert E. Fleming,3 and Dorine W. Swinkels1,2*
BACKGROUND: The peptide hormone hepcidin plays a
central role in regulating dietary iron absorption and
body iron distribution. Many human diseases are asso-
ciated with alterations in hepcidin concentrations. The
measurement of hepcidin in biological fluids is there-
fore a promising tool in the diagnosis and management
of medical conditions in which iron metabolism is
affected.
CONTENT: We describe hepcidin structure, kinetics,
function, and regulation. We moreover explore the
therapeutic potential for modulating hepcidin expres-
sion and the diagnostic potential for hepcidin measure-
ments in clinical practice.
SUMMARY: Cell-culture, animal, and human studies
have shown that hepcidin is predominantly synthe-
sized by hepatocytes, where its expression is regulated
by body iron status, erythropoietic activity, oxygen ten-
sion, and inflammatory cytokines. Hepcidin lowers se-
rum iron concentrations by counteracting the function
of ferroportin, a major cellular iron exporter present in
the membrane of macrophages, hepatocytes, and the
basolateral site of enterocytes. Hepcidin is detected in
biologic fluids as a 25 amino acid isoform, hepcidin-25,
and 2 smaller forms, i.e., hepcidin-22 and 20; how-
ever, only hepcidin-25 has been shown to participate in
the regulation of iron metabolism. Reliable assays to
measure hepcidin in blood and urine by use of immu-
nochemical and mass spectrometry methods have been
developed. Results of proof-of-principle studies have
highlighted hepcidin as a promising diagnostic tool
and therapeutic target for iron disorders. However, be-
fore hepcidin measurements can be used in routine
clinical practice, efforts will be required to assess the
relevance of hepcidin isoform measurements, to har-
monize the different assays, to define clinical decision
limits, and to increase assay availability for clinical
laboratories.
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Iron is required for the function of oxygen-binding
molecules, mainly hemoglobin and myoglobin, and
iron-containing enzymes, including the cytochrome
system in mitochondria. Cellular iron is mostly bound
within iron protoporphyrin (heme) and iron–sulfur
clusters, which serve as enzyme cofactors, or stored
within the core of ferritin multimers. Without ade-
quate iron, cells lose their capacity for electron trans-
port and energy metabolism. However, the redox ac-
tivity of iron can also cause damage, primarily by the
production of reactive oxygen radicals. As such, iron
concentrations must be tightly regulated both at the
cellular and the systemic level. A crucial element in the
maintenance of systemic iron homeostasis is effective
communication between cells that absorb iron from
the diet (duodenal enterocytes), use iron (mainly ery-
throid precursors), and store iron (hepatocytes and tis-
sue macrophages). The peptide hormone hepcidin in-
teracts with the cellular iron exporter ferroportin and
thus is now recognized as the key regulator of systemic
iron homeostasis. Here, we review the major advances
from studies on the structure, kinetics, regulation, and
function of hepcidin and the current state-of-the-art in
hepcidin assays. We furthermore summarize human
studies of hepcidin in physiological and pathophysio-
logical states, and discuss the evidence of the therapeu-
tic potential of modulating hepcidin concentrations.
We conclude by highlighting the most promising ap-
plications of hepcidin assays in diagnostic medicine.
Hepcidin Synthesis and Structure
Human hepcidin is predominantly produced by hepa-
tocytes as a 25 amino acid peptide (2789.4 Da) (1, 2 ),
that is secreted into the circulation. Subsequent amino-
terminal processing of the 25 amino acid form can re-
sult in the appearance of 2 smaller hepcidin forms of 22
and 20 amino acids. These hepcidin peptides form a
hairpin structure, with 4 intramolecular disulfide
bridges (Fig. 1) (3 ). On the basis of some studies, in-
vestigators have reported that hepcidin binds divalent
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metals (Cu2, Fe2, Zn2, and Ni2), but these find-
ings are inconsistent, e.g., some studies have suggested
the presence of iron in the core of the peptide in a
tetrahedral sulfur coordination (4–6), whereas others
provide evidence for an amino-terminal Cu(2)–
Ni(2)-binding (ATCUN) motif (7, 8 ). The ability of
hepcidin to bind iron and other divalent metals sug-
gests there may be a nonhormonal role for hepcidin in
iron metabolism or a conformational mechanism for
uptake of divalent metals as part of hepcidin’s hor-
monal role in regulating ferroportin degradation.
Much is still unknown on the origin of the smaller
isoforms of hepcidin, although data suggest that
calcium-independent tissue activity in pancreas ex-
tracts might lead to the systemic N-terminal truncation
of hepcidin-25 to hepcidin-22, and that dipeptidylpep-
tidase 4 is involved in the processing of hepcidin-22
into hepcidin-20 (9, 10). Under physiological condi-
tions hepcidin-20 and hepcidin-22 are present in the
urine, but not, or at very low concentrations, in the
serum (11–13). Interestingly, these smaller hepcidin
isoforms occur only in serum of patients with diseases
that are associated with increased concentrations of
hepcidin-25, such as acute myocardial infarction
(AMI),4 sepsis, anemia of chronic disease (ACD), met-
abolic syndrome, and chronic kidney disease (CKD)
(Fig. 2) (12–17). In vivo studies in mice have demon-
strated that only full-length 25 amino acid hepcidin
induces significant hypoferremia when injected intra-
peritoneally (18). These findings are corroborated by
in vitro studies that showed that the truncated 22
amino acid and 20 amino acid forms have greatly di-
minished and almost complete loss of ferroportin reg-
ulatory activity, respectively, compared with 25 amino
acid hepcidin (19).
Recent studies have demonstrated hepcidin ex-
pression by cells other than hepatocytes, although at
much lower levels by comparison. These include
kidney tubule, heart, retina, monocytes, neutro-
phils, fat cells, alveolar cells, pancreatic -cells, and
cardiomyocardal cells (20–27 ). The hepcidin pro-
duced by these cells, however, is unlikely to make a
significant contribution to systemic circulating con-
centrations, but may exert local effects in these tis-
sues (see below).
Hepcidin Kinetics
Circulating hepcidin was recently found to be bound to
2-macroglobulin with relatively high affinity and to
albumin with relatively low affinity. On the basis of
theoretical calculations, 11% of hepcidin was estimated
to be freely circulating (28). Whether binding to these
carrier molecules influences the functional properties
of hepcidin is uncertain.
Hepcidin clearance is assumed to occur via cellular
codegradation with ferroportin at its sites of action,
and via excretion by the kidneys. Because of its low
molecular weight and small radius, unbound hepcidin
is likely to freely pass into the glomerular filtrate. In
small studies in humans the fractional excretion of
hepcidin has been calculated to be as low as 0%–5%
(29, 30), either because it is reabsorbed, similarly to
other small peptides, or because it is not freely filtered.
Evidence for the latter explanation comes from the
finding of increases of only 1- to 6-fold of serum hep-
cidin concentrations in patients with glomerular dys-
function (15, 16, 29, 31, 32) compared with the 20- to
30-fold increase of serum 2-microglobulin. The ex-
cretion of the latter low molecular weight protein is
known to be almost completely governed by glomeru-
lar filtration. It is possible that binding to 2-
macroglobulin or other carrier proteins prevents circu-
lating hepcidin from being freely filtered. Alternatively,
the otherwise expected increased circulating concen-4 Nonstandard abbreviations: AMI, acute myocardial infarction; ACD, anemia of
chronic disease; CKD, chronic kidney disease; RE, reticuloendothelial; Tf-Fe2,
transferrin bound iron; TfR, transferrin receptor; HFE, hemochromatosis iron
protein; ERK/MAPK, extracellular signal-regulated kinases/mitogen-activated
protein kinase; BMP/SMAD, bone morphogenetic protein/mothers against de-
capentaplegic homolog (Drosophila); HJV, hemojuvelin; ESA, erythropoiesis-
stimulating agent; EPO, erythropoietin; GDF15, growth differentiation factor-15;
TWSG1, twisted gastrulation protein homolog-1; HIF, hypoxia inducible factor;
DMT, divalent metal transporter; IL, interleukin; C/EBP, CCAAT-enhancer-
binding protein; c, competitive; MS, mass spectrometry; IDA, iron deficiency
anemia; HH, hereditary hemochromatosis; HD, hemodialysis.
Fig. 1. Molecular structure of hepcidin.
A model of the structure of hepcidin-25 according to Jordan
et al. (3 ) is shown, with the -sheets (grey arrows), the
peptide backbone (grey), the disulfide bonds (1–8, 2–4,
3–6, and 5–7) (yellow), positively charged arginine and
lysine residues (blue), and the negatively charged aspartic
acid residue (red).
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trations in patients with decreased renal filtration may
be offset by a compensatory feedback decrease in he-
patic hepcidin production.
It is speculative, but conceivable, that under cer-
tain conditions hepcidin escapes renal tubular reab-
sorption. This lack of reabsorption may play a role in
several disorders of iron metabolism that are associated
with tubular dysfunction and increased concentrations
of urine hepcidin, such as inflammation, iron overload,
and malaria (33, 34). Possible local tubular production
of hepcidin must also be taken into account in the in-
terpretation of urine as a mirror of serum hepcidin
concentrations in such studies (25) as well as possible
defective tubular reabsorption of hepcidin. Additional
studies to investigate the possibility that local urinary
infections or tubular dysfunction can contribute to
hepcidinuria are warranted.
Hepcidin Function
Hepcidin-25 is thought to be the major regulator of
dietary iron absorption and cellular iron release. It ex-
erts its regulatory function by counteracting the func-
tion of ferroportin, the major cellular iron exporter in
the membrane of macrophages, hepatocytes, and the
basolateral site of enterocytes. Hepcidin-25 induces the
internalization and degradation of ferroportin (35–
38), resulting in increased intracellular iron stores, de-
creased dietary iron absorption, and decreased circu-
lating iron concentrations (Fig. 3).
In addition to its role in regulating systemic iron
metabolism, hepcidin may also contribute to host de-
fense. Hepcidin was originally identified as an antimi-
crobial peptide (1, 11). Although in vitro studies sug-
gest bacteriocidal effects of hepcidin, these effects
would require concentrations higher than those ob-
served in the circulation. Such concentrations may be
achieved locally, for instance in phagosomes of infected
macrophages (39). Hepcidin might also contribute in-
directly to host defense by reducing plasma iron con-
centrations. Iron is necessary for microbial growth, and
reductions in plasma iron are bacteriostatic. Moreover,
hepcidin was found to modulate lipopolysaccharide-
induced transcription in both cultured macrophages
and in vivo mouse models (40). This latter observation
suggests a role for hepcidin in modulating acute in-
flammatory responses to bacterial infection.
Hepcidin produced by various cell types other
than hepatocytes (see above) may have local effects in
these tissues. Through an autocrine interaction with
ferroportin, local hepcidin may protect the nearby cells
from iron deficiency, prevent extracellular oxidative
stress, affect inflammatory reponses, and/or deplete ex-
tracellular iron pools that are available for extracellular
pathogens (27, 40–42). Although the smaller forms of
hepcidin do not elicit a hypoferremic response, it is
currently unknown whether they retain other identi-
fied biological functions of hepcidin-25 (e.g., in host
defense or in metal binding) (4, 6, 11, 43).
Fig. 2. TOF MS profiles of serum and urine from a healthy control and serum of a CKD patient (13 ).
The spectra show hepcidin-25 (m/z 2789.4), internal standard (IS) hepcidin-24 (m/z 2673.9), hepcidin-22 (m/z 2436.1), and
hepcidin-20 (m/z 2191.8) isoforms. Note that in contrast to the serum from the healthy control, the CKD serum clearly contains
all 3 hepcidin isoforms. Hep, hepcidin.
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Hepcidin Regulation
Several physiologic and pathologic processes regulate
the synthesis of hepcidin (Fig. 3) [reviewed in (44)].
Situations in which demand for circulating iron is in-
creased (particularly erythropoietic activity) elicit a de-
crease in hepatocellular hepcidin synthesis. These con-
ditions include iron deficiency, hypoxia, anemia, and
conditions characterized by increased erythropoietic
activity. A decrease in hepcidin results in the release of
stored iron and an increase in dietary iron absorption.
On the other hand, infection and inflammation cause
an increase in hepcidin synthesis. This increased syn-
thesis leads to a deficiency of iron available for eryth-
ropoiesis, and is considered to be the mechanism un-
derlying reticuloendothelial (RE) iron sequestration,
intestinal iron absorption impairment, and low serum
iron concentrations characteristic of anemia of chronic
disease.
The functional signaling routes by which (a) iron
status, (b) erythropoietic activity, (c) hypoxia, and (d)
inflammation affect hepcidin expression are increas-
ingly being investigated. These routes comprise 4
highly interconnected regulatory pathways (Fig. 4).
REGULATION BY IRON STATUS
Liver iron stores and circulating transferrin-bound
iron (Tf-Fe2) each provide distinct signals to influence
hepatocyte hepcidin expression (44–46) and are con-
sidered separately (Fig. 4). Circulating transferrin ap-
Fig. 3. Iron uptake and recycling.
Most of the used body iron is recycled from senescent erythrocytes by macrophages, and returned to the bone marrow for
incorporation in erythroid precursors. The liver and RE macrophages function as major iron stores. Importantly, the total amount
of iron in the body can be regulated only by absorption, whereas iron loss occurs only passively from sloughing of skin and
mucosal cells as well as from blood loss. This results in the absorption and loss of 1–2 mg iron every day. Hepcidin, a peptide
produced in the liver, controls the plasma iron concentration by inhibiting iron export by ferroportin from enterocytes and
macrophages. As a consequence, an increase in hepcidin production leads to a decrease in plasma iron concentrations. Hepcidin
expression is regulated by body iron status, inflammation, erythroid iron demand, and hypoxia via regulation pathways involving
the expression of the genes HFE, transferrin receptor 2 (TFR2), and hemochromatosis type 2 (juvenile) (HFE2) (also known as
HJV). Adapted from (142, 223 ).
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pears to be sensed via a hepatocellular complex, which
includes transferrin receptor-1 (TfR1), TfR2, and
hemochromatosis iron protein (HFE). Defects in TfR2
and HFE lead to decreased hepcidin concentrations via
the extracellular signal-regulated kinases: the mitogen-
activated protein kinase (ERK/MAPK) pathway and/or
the bone morphogenetic protein/mothers against de-
capentaplegic homolog (Drosophila) (BMP/SMAD)
pathway (Fig. 4). Intracellular iron stores communi-
cate with hepcidin via BMPs, particularly BMP-6, in a
paracrine or autocrine fashion. These extracellular sig-
naling molecules act on hepatocellular BMP receptors
to activate the intracellular SMAD signaling pathway
and increase hepcidin transcription. Hemojuvelin
(HJV), a BMP coreceptor (47), is crucial for hepcidin
expression because various hepcidin regulatory path-
ways converge at this membrane-bound protein. Un-
der low iron conditions, membrane-bound HJV is
Fig. 4. Molecular and functional pathways of hepatocyte hepcidin synthesis.
Three molecular pathways can be distinguished: the HFE/TfR2, BMP/SMAD, and JAK/STAT. This proposed model depicts 2 iron
signals to hepcidin, 1 mediated by intracellular iron stores (Fe) and the other by circulating iron (Tf-Fe2). Hepatocellular iron
stores increase the expression of BMP-6, which serves as an autocrine factor by interacting with surface BMP receptors. HJV
is a BMP coreceptor that augments BMP binding. The consequent activation of intracellular SMAD proteins transduces a signal
to increase hepcidin transcription. HJV is subject to cleavage by furin, which is regulated by iron and hypoxia, to form a soluble
component (sHJV) (61 ). sHJV can subsequently act as a decoy coreceptor and antagonist of BMP-6 induced hepcidin synthesis.
Under low iron conditions membrane bound HJV is also cleaved by matriptase-2 (scissors) again weakening the BMP-6 signal.
Extracellular Tf-Fe2 mediates a second iron signal. In this scheme, Tf-Fe2 displaces HFE from TfR1. HFE is then liberated to
interact with TfR2. The HFE–TfR2 complex activates hepcidin transcription via BMP/SMAD signaling. Several studies have
provided indirect evidence for the involvement of the hepatic ERK/MAPK signaling pathway in hepcidin regulation by iron
through TfR2 and/or HFE [reviewed in (44 )]. Recent studies in mice, however, demonstrate that acute and chronic enteral iron
administration did not activate the ERK/MAPK pathway, which suggests that this route may not be of physiological relevance
for iron homeostasis in vivo (46 ). Hypoxia influences liver-specific stabilization of HIF-1, which induces matriptase-2 and the
subsequent cleavage of HJV (62 ). The latter pathway may be synergistic to the increased release of sHJV upon its cleavage by
furin under hypoxic conditions. Erythropoiesis is controlled in part by EPO production in the kidney and communicates with the
hepatocyte by the proteins GDF15 and TWSG1, which inhibit the BMP/SMAD signaling to hepcidin. Inflammatory stimuli, such
as IL-6, induce hepcidin synthesis through the janus kinase/signal transducer and activator of transcription-3 (JAK/STAT)
pathway. These pathways have recently been reviewed (44 ). Adapted from (133, 224 ). pO2, partial oxygen pressure; sTfR:
soluble TfR; BMPR, BMP receptor; IL-6R: IL-6 receptor.
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cleaved by matriptase-2, a transmembrane protease
serine 6, encoded by the transmembrane protease, ser-
ine 6 (TMPRSS6)6 gene, expressed predominantly in
the liver (48, 49). This cleavage by matriptase-2 weak-
ens the BMP signaling.
REGULATION BY ERYTHROPOIETIC SIGNALS
Administration of erythropoiesis-stimulating agents
(ESA) was found to decrease (hepatocyte) hepcidin
production in murine, human, and in vitro stud-
ies (50–53 ). Erythropoiesis requires considerable
amounts of iron, so suppression of hepatic hepcidin
synthesis by erythropoietic signals is of great physio-
logical importance. However, how erythropoiesis reg-
ulates hepcidin is not clear yet. The hypothesis that
erythropoietin (EPO) acts directly on hepatocyte re-
ceptors in cell culture (51) could not be confirmed in
animal models for anemia, which showed that de-
creased hepcidin expression depends on erythropoiesis
and is not directly mediated by EPO (53, 54).
Recent observations suggest that the erythropoi-
etic signal may include 1 or more proteins released at
sites of active erythropoiesis, i.e., growth differentia-
tion factor-15 (growth differentiation factor-15
(GDF15) and twisted gastrulation protein homolog-1
(TWSG1). These molecules, like BMPs are members of
the transforming growth factor- family and thus pos-
sibly act through effects on the BMP/SMAD pathway
(Fig. 4) (55–57). Correlations between the expression
of TWSG1 expression and serum iron parameters and
serum hepcidin concentrations have not yet been de-
termined in humans. Neither of these factors, however,
appears to be required to mediate the decrease in hep-
cidin observed with EPO administration. It is likely
that additional erythropoietic factors downregulating
hepcidin expression will be identified.
REGULATION BY HYPOXIA
Decreased hepcidin expression has been reported in
response to hypoxia in vivo (58, 59). This effect might
be attributable in part to the effect of hypoxia on EPO
expression and thus erythropoietic activity and/or pos-
sibly via a direct interaction with hepatocyte receptors
(51). In addition, the lower hepcidin concentrations
observed in response to hypoxia may be attributed to
liver-specific stabilization of hypoxia-inducible factor
(HIF)-1 (60), with downstream effects on the BMP/
SMAD signaling pathway (61, 62). Whether HIFs di-
rectly bind to the hepcidin promoter is currently con-
troversial. However, there are indirect mechanisms by
which HIFs may regulate hepcidin expression. In-
creased HIF activity is associated with increased
matriptase-mediated cleavage hemojuvelin and thus
decreased hepcidin expression (62). Moreover, the sys-
temic iron regulation by the hepcidin-ferroportin axis
acts in harmony with the enterocyte cellular iron ho-
meostasis control system. Mice lacking intestinal
HIF2 have decreased expression of both ferroportin
and divalent metal transporter 1, the principal iron im-
porter at the apical surface of duodenal enterocytes,
and thus fail to induce iron absorption even upon low-
ering of hepcidin expression (63). These data suggest
that in hypoxic (or iron deficient) conditions, expres-
sion of HIF2 promotes iron absorption from the in-
testine via increased activity of divalent metal trans-
porter 1 and ferroportin. This result implies that
HIF2-induced changes in iron transport can override
the effects of the hepcidin-ferroportin regulatory axis.
REGULATION BY INFLAMMATION
The increase in hepcidin expression with inflammation
is primarily mediated by interleukin-6 (IL-6). The hep-
atocellular interaction of IL-6 with its receptor acti-
vates the janus kinase/signal transducer and activator
of transcription-3 signaling pathway (59, 64–66).
Hepcidin expression is also increased by oxidative or
endoplasmic reticulum stress. This stress response
can be controlled by the transcription factor cAMP-
response-element-binding-protein-H (67 ) or by
the stress-inducible transcription factors CCAAT-
enhancer-binding protein (C/EBP) and C/EBP-
homologous protein (68). Alcohol-dependent down-
regulation of C/EBP, probably through radical
oxygen species, might be responsible for a decrease of
hepcidin expression and subsequent (mild) iron over-
load in heavy drinkers (69, 70).
INTERACTION BETWEEN HEPCIDIN REGULATORY PATHWAYS
The activation of the hepcidin regulatory pathways de-
scribed above are all dependent on interactions of cir-
culating or autocrine factors with hepatocyte mem-
brane sensors to control the hepatic production of
hepcidin for proper maintenance of systemic iron ho-
meostasis [reviewed in (44)]. There are multiple po-
tential opportunities for cross communication among
these pathways, and experimental evidence shows that
these pathways do not function completely indepen-
dently of each other.
Serum hepcidin concentrations appear to be de-
termined by the relative strengths of the individual reg-
ulators. In an attempt to delineate relative strengths of
these regulators in patients with iron metabolism dis-
orders, we constructed an algorithm to predict relative
hepcidin concentrations based on certain serum pa-
6 Human genes: TMPRSS6, transmembrane protease, serine 6; HFE, hemochro-
matosis; PER1, period homolog 1 (Drosophila); TIMELESS, timeless homolog
(Drosophila); CLOCK, clock homolog (mouse); HAMP, hepcidin antimicrobial
peptide; TFR2, transferrin receptor 2; HFE2, hemochromatosis type 2 (juvenile).
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rameters (C-reactive protein, Tf saturation, and solu-
ble TfR) that reflect inflammation, serum iron, and
erythropoietic regulatory pathways (71). This algo-
rithm provided insight into the interrelation of these
pathways by showing that hepcidin inhibition by
erythropoiesis strongly interferes with hepcidin up-
regulation by iron and that inflammation strongly in-
creases hepcidin regardless of iron status and erythro-
poietic activity. These findings are in agreement with
results of studies demonstrating that high erythroid de-
mand for iron blunts hepcidin induction by a concom-
itant inflammatory response (50, 72–75). Other stud-
ies have shown that increased and/or ineffective
erythropoiesis blunts the induction of hepcidin by in-
creased body iron stores (52, 73). Reports on the effect
of a defective HFE/TfR2 pathway on hepcidin upregu-
lation by inflammation are not consistent. One study
showed a blunted hepcidin response to inflammatory
stimuli in hemochromatosis (HFE) knock-out mice
(76), whereas results of other studies of the same mice
or a patient with an HFE mutation suggest that inflam-
matory induction of hepcidin is independent from the
HFE protein (77, 78). Clearly, future large and well-
designed studies are needed to improve our under-
standing of this hepcidin regulatory network in various
disorders of iron metabolism.
HepcidinMethods
Since the discovery of hepcidin, there has been a sub-
stantial interest in developing a reliable assay of the
peptide hormone in body fluids. Accurate determina-
tion of hepcidin concentrations in serum and urine will
improve our understanding of iron metabolism disor-
ders and may provide a useful tool in the differential
diagnosis and clinical management of such diseases.
CHALLENGES FOR HEPCIDIN ASSAYS
The quantification of hepcidin has been found to be
complicated by its tendency to aggregate (79) and to
stick to laboratory plastics, necessitating implementa-
tion of robust laboratory procedures. Furthermore,
progress in developing a conventional immunochemi-
cal hepcidin assay has been hampered by difficulties in
generating specific antihepcidin antibodies in hosts
such as rabbits. This difficulty is due to the small and
compact structure of hepcidin, which leaves scarce an-
tigenic epitopes (Fig. 1), and the high degree of conser-
vation of hepcidin among a wide range of species,
which diminishes the elicitation of an immune re-
sponse in host animals (50).
Interpretation of hepcidin test results might be in-
fluenced by whether the various assays are detecting
freely circulating hepcidin, hepcidin bound to a carrier
protein, or both of these hepcidin species. Lastly, the
presence of hepcidin-22 and -20 isoforms, which play
no role in the regulation of iron metabolism, can inter-
fere with the quantification of hepcidin-25 in immu-
noassays that use antibodies that react with all of these
hepcidin isoforms.
FIRST-GENERATION (SEMIQUANTITATIVE) HEPCIDIN ASSAYS
In several early studies a commercial serum-based im-
munoassay was used that measures the hepcidin pre-
cursor prohepcidin rather than the bioactive peptide
(80). The relevance of these studies is questionable,
because of the fact that prohepcidin concentrations
correlate with neither urinary nor serum hepcidin con-
centrations, nor do they correlate with relevant physi-
ological responses (71, 81–83). The first assays to mea-
sure bioactive hepcidin-25 were an immunodot
assay (59), SELDI-TOF mass spectrometry (MS)
(12, 15, 84). However, these assays could be used to
measure hepcidin only in a semiquantitative manner.
SECOND-GENERATION (QUANTITATIVE) HEPCIDIN ASSAYS
In recent years, substantial progress has been made by
the introduction of an internal standard to quantify
hepcidin-25 in serum and urine by an updated
TOF-MS assay (13, 30). In addition, Ganz et al. (29)
developed a competitive (c)ELISA for human serum
hepcidin. Other groups have also reported reliable hep-
cidin assays that can be divided in 3 main methodolo-
gies: (a) MS (85–95); (b) immunochemical assays,
comprising cRIA (96, 97), cELISA (13, 29, 98, 99), and
a 2-site ELISA (100); and (c) a ligand-binding assay
(43) (Table 1). Of the currently available commercial
immunochemical research kits for serum hepcidin, we
found the RIA and enzyme-immunoassay kits of
Bachem (purchased November 2009 and August 2010,
respectively) to be suitable to differentiate between
hepcidin concentrations in serum samples of controls
and patients with various iron disorders, whereas the
bioactive hepcidin kit of DRG Instruments, (purchased
October 2009) gave similar concentrations for all sam-
ples and could not discriminate between iron metabo-
lism disorders (unpublished results).
STRENGTHS AND LIMITATIONS OF QUANTITATIVE PLASMA AND
URINE HEPCIDIN ASSAYS
MS assays require relatively expensive equipment, but
they have the advantage of distinguishing between
hepcidin-25, -22, and -20 (13). ELISA assays will
measure total hepcidin concentrations, with (depend-
ing on the specificity of the antibody) different con-
tributions from each of these 3 isoforms. However,
this concern might be overcome by exploiting anti-
bodies that are hepcidin-25 specific (100). At the same
time it should be noted that the relevance of measur-
ing hepcidin-25 instead of total hepcidin for clinical
Reviews
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decision-making has not been systematically investi-
gated. Immunoassays have the potential for more
widespread use in clinical laboratories. Furthermore,
sample throughput is likely to be higher for ELISA than
for MS assays. However, MS methods can also be au-
tomated (101, 102), and would have to be optimized
for hepcidin because its amphiphatic character makes
it readily stick to laboratory plastics, especially when
relatively small sample volumes are used in large tubes.
Further comparison of the analytical characteris-
tics of various published assays is incomplete, because
not all studies have reported these characteristics in
accordance with the STARD (STAndards for the Re-
porting of Diagnostic accuracy studies) procedures
(103) or validated the reported assays according to rec-
ommendations of the International Conference of the
Harmonization (ICH) of analytical procedures (104).
Nonetheless, the scientific and medical community
was informed on the status and agreement of the cur-
rent hepcidin methods by a recent international send-
out of samples for urine and serum hepcidin measure-
ment in 2009, the so-called “Round Robin 1.” In this
study the correlations between the participating meth-
ods were generally high and the between-sample and
analytical variation of most methods were similar
(105). However, absolute hepcidin concentrations dif-
fered widely between the assays. This latter variation is
not surprising given the absence of a reference method
(106) and a validated commutable calibrator or other
material for assay harmonization. These differences in
level assignment hinder the comparability of data col-
lected by use of the various methods and preclude the
definition of universal reference intervals and cutoff
values for clinical decision making. Therefore, a second
Round Robin for plasma hepcidin was initiated to ex-
plore word-wide hepcidin harmonization by exchang-
ing synthetic materials for assay harmonization and
native samples. Results are expected during 2011 (un-
published data).
Urine hepcidin measurements may be attractive,
especially for use in research and measurements in chil-
dren and patients in the underdeveloped world, be-
cause this matrix allows noninvasive sampling. Never-
theless, although a significant relationship was found
between the hepcidin concentrations of urine–serum
sample pairs from healthy controls and patients with
disorders of iron metabolism (12, 29, 107), urine hep-
cidin concentrations may not always accurately reflect
serum hepcidin concentrations. Interpretation of uri-
nary hepcidin data is difficult because urine concentra-
tions may also depend on glomerular filtration, tubular
reabsorption, local production by tubular epithelial
cells (25), and production by interstitial inflammatory
cells (108). These issues make measurement of hepci-
din somewhat disadvantageous in urine compared to
serum and imply that for reliable interpretation of
urine hepcidin concentrations as an alternative for se-
rum concentrations, information on renal hepcidin
production and handling is needed. Moreover, in a
previous study we found a relatively high (pre)analyti-
cal variation for urine hepcidin measurements (107).
Another potential drawback of urine hepcidin mea-
surements is its sensitivity to oxidation (30) and the
relatively high concentration of the smaller hepcidin
isoforms, which cannot be distinguished from
hepcidin-25 by most immunoassays. Altogether, these
limitations should be kept in mind during the interpre-
tation of urine hepcidin data and the decision to de-
velop dedicated point-of-care devices for urine hepci-
din measurements.
Table 1. Currently available hepcidin methods.
MS Reference Immunochemical Reference
Hepcidin
binding Reference
HPLC/UPLCa MS/MS Kobold et al. (87)
Bansal et al. (88)
c-ELISA Kroot et al. (13) (Bachem)
Ganz et al. (29)
Koliaraki et al. (98)
Schwarz et al. (99)
Q-TOF LC-MS Crockett et al. (92)
LC-MS/MS Murphy et al. (85)
Murao et al. (86)
Li et al. (89)
c-RIA Bushbridge et al. (96) (Bachem)
Grebenchtchikov et al. (97)
HBD assay De Domenico et al. (43)
MALDI-TOF MS Kroot et al. (13)
Swinkels et al. (30)
Anderson et al. (91)
Sandwich ELISA Butterfield et al. (100)
SELDI-TOF MS Campostrini et al. (90)
Altamura et al. (94)
Ward et al. (95)
a UPLC, ultra-high pressure LC; MS/MS, tandem MS; Q, quadrupole; HBD, hepcidin-binding domain.
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REFERENCE INTERVALS FOR SERUM HEPCIDIN
Small and large studies of healthy controls have re-
vealed considerable interindividual variation in hepci-
din concentrations, resulting in wide reference inter-
vals (12, 29, 96, 97, 107, 109). This situation suggests
that reference intervals may have limitations when
used for the interpretation of individual hepcidin con-
centrations. It appears that hepcidin values, like those
of other hormones, should be interpreted in the con-
text of other indices of iron metabolism. For instance, it
is possible that “normal” concentrations of hepcidin in
iron deficiency anemia (IDA) are inappropriately high,
and perpetuate iron restriction.
The wide reference intervals may be attributed at
least partly to the increase of hepcidin concentrations
in the course of the day (12, 29, 96, 97, 107). This ap-
parent circadian rhythm of hepcidin concentrations
may be regulated by transcription factors such as up-
stream stimulatory factor and c-Myc/Max through
E-boxes (110). Genes that are regulated through
E-boxes, including the clock genes period homolog 1
(Drosophila) (PER1), timeless homolog (Drosophila)
(TIMELESS), and clock homolog (mouse) (CLOCK),
tend to be under circadian rhythmic transcriptional
control. However, circadian variation in hepcidin
could be secondary as well, because it might be driven
by the influence of iron intake during the day. As such,
we recommend standardization of sampling time
to minimize within-individual and (pre)analytical
variability in clinical studies exploiting hepcidin
measurements.
To date, differences in hepcidin concentrations
between the sexes have not been consistently found
(12, 29, 85, 96, 97, 107). We recently assessed serum
hepcidin reference intervals stratified by age and sex
stratified in a reference set selected from a large, well-
phenotyped sample of the general population of the
Dutch city of Nijmegen (109). We observed lower se-
rum hepcidin concentrations in premenopausal
women than in postmenopausal women (median 4.1
nmol/L vs 8.5 nmol/L) (109). Hepcidin concentrations
in men were constant over age (median 7.8 nmol/L). In
this study serum hepcidin was strongly associated with
serum ferritin in men and women, confirming findings
of smaller previous studies (29, 30, 107, 111, 112).
Hepcidin concentrations have not been consistently
compared between races and there are few studies in
children (113–120). To the best of our knowledge there
are 2 reported studies of hepcidin concentrations in
pregnant women, both of which showed that hepcidin
concentrations in anemic pregnant women is lower
than in nonanemic pregnant women, but are not re-
lated to cord-blood or newborn hepcidin or other fetal
iron parameters (114, 121).
As we discussed previously, basal hepcidin con-
centrations greatly depend on the applied measure-
ment method (105). This situation implies that until
harmonization is achieved, reference intervals as well
as clinical decision limits for certain patient popula-
tions specific to the assay methods should be used. Har-
monization of the methodologies, by using reliable cal-
ibrators or other materials for harmonization, will
enable translational scientists as well as physicians in
clinical practice around the world to collectively define
criteria for the use of hepcidin assays in diagnosis, stag-
ing, monitoring, and assessing treatment indications of
iron disorders.
Hepcidin in Human Iron Disorders
The development and validation of hepcidin assays
paved the way for a large number of human studies that
considerably increased our understanding of the phys-
iology and pathophysiology of iron homeostasis and
moreover demonstrated promising applications for
hepcidin in diagnostic medicine (Table 2).
DISORDERS ASSOCIATED WITH HEPCIDIN DEFICIENCY
Hepcidin in hereditary hemochromatosis (HH). HH
comprises several genetic disorders of iron homeostasis
characterized by body iron excess. This results in body
iron overload, which can progress to organ injury, such
as liver fibrosis and cirrhosis (122). Patients with most
forms of HH have the inability to appropriately up-
regulate hepcidin synthesis in response to increased
iron stores. This dysregulation is caused by defects in
certain genes encoding for positive regulators of hepci-
din (HFE, TfR2, HJV), or, rarely, the hepcidin gene
[hepcidin antimicrobial peptide (HAMP)] itself [re-
viewed in (123, 124)]. The low hepcidin state relative
to ferritin in these patients (125–127) leads to in-
creased intestinal iron absorption and body iron over-
load. Hepcidin concentrations in untreated patients
with rare juvenile forms of HH tend to be very low
(127). Mutations in the gene encoding the cellular iron
exporter ferroportin can also cause HH. However,
there are 2 classes of ferroportin mutations with differ-
ent phenotypic consequences: loss of hepcidin regula-
tion and loss of ferroportin function (36, 128–130).
The former defect leads to greater than normal ferro-
portin activity and thus is often described as a “gain of
function” ferroportin mutation. As expected, patients
with these mutations have a phenotype similar to clas-
sical HH. However, because the defect is downstream
of hepcidin, these patients do not have low hepcidin
concentrations. After treatment with phlebotomy that
normalized iron stores (as assessed by serum ferritin),
these patients have been found to have serum hepcidin
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concentrations or serum hepcidin/ferritin ratios
within or above reference intervals (128, 131). The rel-
atively high hepcidin concentrations in some patients
might be a consequence of the transferrin saturation
that remained increased despite phlebotomy. By con-
trast, mutational defects that result in the loss of ferro-
portin function cause cellular iron overload due to
compromised iron export. Such patients thus have
some phenotypic characteristics which vary from those
of classical HH and have been reported to have high
(urinary) hepcidin concentrations when untreated
(127).
Iron-depleted HFE C282Y patients have been
shown to have very low serum hepcidin concentra-
tions, reflecting the combined effects of the HFE
mutation and phlebotomy on hepcidin expression
(125, 132). These patients demonstrated an exagger-
ated increase in serum iron concentrations upon oral
iron loading (132). This observation draws further at-
tention to the concern that lowering hepcidin concen-
trations by phlebotomy in HH patients may exacerbate
the underlying pathophysiology, exacerbating the ex-
cess release of iron into the circulation, with an ensuing
vicious circle that leads to the need for more frequent
maintenance phlebotomies in HH patients (125, 126).
We foresee the following potential applications of
hepcidin measurements in patients diagnosed with or
suspected for HH: (a) screening for the presence of HH
in patients with increased ferritin concentrations; (b)
prioritization of genes to be investigated (very low hep-
cidin concentrations point to juvenile HH forms); (c)
prediction of which C282Y-homozygous patients will
be at risk for iron overload; and (d) monitoring of phle-
botomy treatment (123, 133).
Hepcidin in iron-loading anemias. In congenital iron-
loading anemias, such as -thalassemia (major and in-
termedia) and congenital dyserythropoietic anemia I
and II, but also in acquired forms such as myelodys-
plastic syndrome types RA (refractory anemia) and
RARS (RA with ringed sideroblasts), the diseased
erythron dysregulates iron homeostasis by inhibiting
hepcidin synthesis, even in the presence of iron over-
load (134–140). The hepcidin/ferritin ratio is also
found to be low in patients with these disorders
(135, 137, 138, 140–142). The consequences of inef-
fective erythropoiesis on hepcidin expression thus ap-
pear to trump the consequences of excessive iron
stores. In sickle cell disease, patients demonstrate the
additional confounding factor of inflammation. Possi-
Table 2. Most promising applications of serum hepcidin in diagnostic medicine.
Disease condition Expected hepcidin concentrationsa
Potential added value of hepcidin
diagnostics
Classical hereditary
hemochromatosis
Low, maybe compensated by iron
overload over time
Screen for the presence of hemochromatosis
Predict which homozygotes will be at risk for
iron overload
Determine the phlebotomy interval
Prioritize genes to be investigated
Iron-loading anemias Low, maybe compensated by transfusional
iron overload over time
Identify the most severely affected patients
Predict and monitor (parenchymal) iron
overload
Acquired forms of iron overload Miscellaneous A marker of iron dysregulation
Iron-refractory iron deficiency
anemia
Inappropriately high Screen for primary defect in hepcidin regulation
Inflammation and infection High Differentiate ACDb and IDA
Guide iron supplementation therapy
Chronic kidney diseases High, decreases upon EPO treatment Predict EPO response
Guide treatment with EPO, intravenous iron
Acute kidney injury Low (urine) Diagnose acute kidney injury
Treatment with hepcidin
antagonists and agonists
Depends on the disorder Monitor and assess indications
a In serum, unless stated otherwise.
b ACD, anemia of chronic disease; IDA, iron deficiency anemia; EPO, erythropoietin.
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bly the consequent increase in hepcidin by inflamma-
tory signals attenuates iron toxicity than would other-
wise be observed in sickle cell disease patients
(141, 143).
In patients with heritable forms of anemia, infor-
mation on hepcidin concentrations may be valuable
for identifying the most severely affected patients
and predicting and monitoring parenchymal iron
overload.
Hepcidin in acquired forms of nonhemochromatotic iron
overload. Several nonhereditary liver diseases such as
excessive alcohol consumption, nonalcoholic fatty
liver disease and nonalcoholic steatohepatitis are asso-
ciated with mild hepatic iron overload. In these so-
called nonhemochromatotic iron overload diseases,
hepcidin concentrations are increased, but relatively
low for the level of iron overload, suggesting ineffective
liver iron sensing. In these conditions, dysregulation of
hepcidin synthesis as a consequence of reactive oxygen
species, endoplasmic reticulum stress, and cytokine tu-
mor necrosis factor-–mediated pathways may con-
tribute to relatively decreased hepcidin synthesis and
iron accumulation (59, 67–70, 144). Measurement of
serum hepcidin may prove to be useful as a marker of
iron dysregulation in these forms of iron overload.
Hepcidin in IDA. In IDA patients, and also in patients
with low ferritin concentrations without anemia, sec-
ondary to blood losses or insufficient dietary intake,
hepcidin concentrations have been found to be very
low, often below the lower limit of detection of the
employed assays (13, 29).
Effect of iron administration on hepcidin concentrations.
Several studies have addressed the relationship be-
tween iron absorption and hepcidin concentrations. In
healthy human volunteers hepcidin in urine and serum
increased upon oral iron dosing, although nonre-
sponders were reported (29, 59, 112, 145–147). Some
studies report a weak, but significant, negative correla-
tion between serum hepcidin concentrations and iron
absorption (112, 146, 147). These results suggest that
quantification of serum hepcidin concentrations could
be a predictor for the therapeutic effect of oral iron
administration. Moreover, the response of the hepci-
din to oral iron might prove to be a useful test to eval-
uate iron absorption in iron deficiency.
DISORDERS ASSOCIATED WITH HEPCIDIN EXCESS
Hepcidin in iron-refractory IDA. Most patients with
iron-refractory IDA are resistant to dietary iron sup-
plementation, owing to a defect in the TMPRSS6 gene
encoding matriptase-2. Repeated intravenous iron in-
fusions, on the other hand. have been reported to (par-
tially) increase hemoglobin and mean cell volume
(119, 120, 148–151). Loss of matriptase-2 activity re-
sults in an inability to reduce hepcidin synthesis during
iron deficiency (49). Accordingly, patients have in-
creased innate hepcidin concentrations resulting in ex-
tremely low transferrin saturation percentages and fer-
ritin concentrations in the lower range of the reference
interval (118, 119, 120, 148–151). Therefore, assess-
ment of hepcidin concentrations can serve to exclude
or raise the suspicion for matriptase-2 deficiency in
unexplained IDA and thus help to avoid the unneces-
sary burden associated with multiple diagnostic testing
and delayed or ineffective treatment.
Hepcidin in infectious and inflammatory diseases. Infec-
tions are associated with marked changes in iron ho-
meostasis (152). Malaria-associated anemia has been
found to be associated with low serum iron and in-
creased hepcidin concentrations, causing iron with-
holding in the RE system that ultimately leads to iron-
restricted erythropoiesis (115, 118, 153–156). Possibly,
these increased hepcidin concentrations might be ad-
vantageous in the protection against extracellular
growing microorganisms by decreasing the extracellu-
lar supply of iron. On the other hand, increased hepci-
din concentrations may lead to iron deficiency and
blunt the efficacy of iron fortification programs by de-
creasing iron absorption (157). Conversely, the in-
creased hepcidin concentrations seen with inflamma-
tion might increase the virulence of bacteria that
depend on macrophage iron for their proliferation
within these cells (e.g., Salmonella and Mycobacteria
spp.). Such pathogens are common in malaria-endemic
regions. Perhaps, in such areas, untargeted iron supple-
mentation among iron-replete children might result in
severe adverse events by increasing the proliferation of
latent pathogens (158).
Hepcidin has been demonstrated to be important
in the pathogenesis of other infectious agents as well. In
patients with hepatitis C virus, increased transferrin
saturation and increased concentrations of serum fer-
ritin and hepatic iron have been observed. Consistent
with this iron loading, low hepcidin concentrations
have been found in these patients, along with other
changes in the expression of iron-transport genes [re-
viewed in (159)]. In a pediatric study, no relationship
was found between Helicobacter pylori infection and
hepcidin and between cytokine and hepcidin concen-
trations, suggesting that H. pylori–induced inflamma-
tion does not influence iron status through increased
hepcidin production in childhood (118).
In ACD, IL-6 and other cytokines induce hepcidin
concentrations, resulting in iron sequestration in mac-
rophages and leading to hypoferremia. Subsequently,
iron availability for the erythron becomes limiting
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and contributes to the development of ACD
(59, 75, 81, 160, 161). Elderly people often suffer from
anemia. In a recent study among elderly individuals
(65 years old), the presence of anemia could not be
attributed to increased hepcidin concentrations, be-
cause urinary hepcidin concentrations were signifi-
cantly lower among participants with inflammation
anemia and iron deficiency compared with nonanemic
controls. This finding raises the possibility that in this
population hepcidin-independent mechanisms can
cause hypoferremia and anemia of inflammation,
and/or that even otherwise “normal” hepcidin concen-
trations are sufficient to sustain anemia once it is initi-
ated (162).
At present, there is no single laboratory test that
can definitively distinguish ACD from IDA (160, 163).
Therefore, differentiation between these conditions is
often achieved by combining various biochemical
markers of iron metabolism. Studies to assess the role
of hepcidin in ACD are complicated by the lack of a
gold standard methodology. As a result the outcomes
of studies to assess the diagnostic value of hepcidin
largely have depended on the definition of surrogate
gold standards. Some studies showed that hepcidin is
an appropriate marker in the differentiation of ACD
and IDA/ACD but not of IDA and IDA/ACD (75),
whereas others have reported that hepcidin allowed
distinguishing IDA from IDA/ACD but not ACD from
IDA/ACD (13, 164). Results of another study have sug-
gested that hepcidin concentrations can serve as an ap-
propriate marker to differentiate between all 3 groups
(165).
Hepcidin measurements appear to have potential
utility in diagnostic algorithms to distinguish IDA
from ACD and the combined presence of IDA/ACD.
Further studies in which hepcidin response to iron sup-
plementation is used as a proxy for the gold standard of
iron status would be informative. Hepcidin measure-
ment also may be useful in anticipating consequences
of iron supplementation in infectious and inflamma-
tory diseases.
Hepcidin in renal diseases. The introduction of ESAs,
such as EPO, has allowed effective treatment of anemia
in patients with CKD. However, the optimal target
concentration of hemoglobin is debated, and many pa-
tients become ESA resistant. Soon after its discovery
and during the years thereafter, hepcidin was recog-
nized as potentially relevant in CKD because it may be
responsible for the often-observed imbalance between
iron homeostasis and ESA resistance (50, 166). As such
hepcidin was described as a promising companion di-
agnostic marker to predict ESA responsiveness, and to
guide treatment with ESA and intravenous iron. In ad-
dition, hepcidin’s potential to become a target of treat-
ment was quickly acknowledged. These promises
brought about a large series of studies that examined
hepcidin concentrations in patients with CKD. In
general, these studies have reported increased hepci-
din concentrations in CKD patients compared with
healthy controls (15, 16, 29, 31, 32, 88, 89, 96, 167–
169). Because these patients tend to be anemic, even a
mild hepcidin excess can be considered to be inappro-
priately high for the level of anemia. Virtually all stud-
ies on hepcidin in CKD patients revealed a strong pos-
itive relationship between hepcidin and ferritin
concentrations. Some of these studies also demon-
strated correlations between hepcidin and iron or
transferrin saturation (169, 170). Hepcidin in CKD
also has been associated with iron-restricted eryth-
ropoiesis, as reflected by the relation of hepcidin
with lower hemoglobin and/or reticulocyte counts
(31, 169, 171). Furthermore, CRP and IL-6 were
shown to be less relevant predictors in the setting of
renal insufficiency (16, 170, 172–175). Intravenous
iron administration was found not to influence hepci-
din concentrations in hemodialysis (HD) patients that
were withheld from iron and ESA therapy for 2 weeks
(169), whereas it increased hepcidin in iron-naı¨ve
CKD patients (31, 96). In HD patients on ESA, hepci-
din did not predict which patients increase their hemo-
blobin after iron loading (17). As mentioned earlier,
several investigators have reported a decrease in
hepcidin concentrations after EPO administration
(31, 50, 169, 170). These findings again suggest that
the erythroid demand for iron might be a more
powerful regulator of hepcidin expression than
inflammatory- or iron-induced hepcidin formation.
To allow proper interpretation of the effect of the
erythropoietic drive on hepcidin production, EPO and
hepcidin concentrations should be assessed simultane-
ously in selected patients with anemia of CKD.
Interestingly, hepcidin also was evaluated as a pre-
dictor of ESA response in several relatively small stud-
ies in humans. One study revealed that hepcidin
concentrations of EPO responders did not differ
from those of hyporesponders (176), whereas cross-
sectional studies among HD patients and a prospective
study among patients with combined CKD and
chronic heart failure revealed that nonresponders had
low hepcidin concentrations (32, 170, 177). Possibly
hepcidin should be regarded as a marker of response
rather than resistance to ESA treatment in these
patients.
Although hepcidin is a promising companion di-
agnostic for ESA therapy, patients with renal insuffi-
ciency are a rather complex population in which con-
sistent results have been difficult to obtain (175).
Clinical stability, time of sampling in relation to iron
and ESA therapy, and iron and EPO dosage and dialysis
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regimens differ between studies and are likely to influ-
ence results. Therefore, there is need for further studies
on serum hepcidin concentrations in larger and well-
designed studies to resolve the aforementioned dis-
crepancies in the literature.
In addition to its potential as a marker of iron me-
tabolism in patients with CKD, combined urinary and
serum hepcidin concentrations may serve as a marker
for renal disease itself. For instance, studies suggest that
smaller increases in urinary hepcidin, relative to serum
hepcidin, may be associated with a greater risk of acute
kidney injury after coronary artery bypass graft surgery
in patients with stable renal function (178, 179). In a
study on urine biomarkers in patients with lupus ne-
phritis, urinary concentrations of hepcidin, possibly
secreted by interstitial inflammatory cells, were identi-
fied as markers of renal lupus nephritis flare (108).
Hepcidin in obesity-related diseases. Adipose tissue is an
active endocrine organ that releases several cytokines
and adipokines, which can contribute to the develop-
ment of a low-grade systemic inflammation. Further-
more, adipose tissue also can produce hepcidin (21).
The low-grade inflammation in obese and dysmeta-
bolic iron overload syndrome patients, (characterized
by the association of increased body iron stores and
metabolic features), is associated with increased hepci-
din concentrations, leading to poor iron absorption
and causing ACD (116, 117, 180, 181). Serum hepci-
din concentrations decreased, and an increase in iron
status and intestinal absorption was observed in indi-
viduals with weight loss (182, 183). Thus, in chronic
mild inflammatory conditions, such as obesity or the
metabolic syndrome, even a mild hepcidin excess may
be sufficient to alter the balance between iron loss and
iron uptake toward iron deficiency.
Hepcidin in heart diseases. Anemia of chronic heart fail-
ure has been found to be associated with low hepcidin
concentrations, making (low-grade) inflammation less
likely as the sole underlying mechanism (184, 185). A
study on acute cardiac ischemia showed a transient in-
crease in serum hepcidin-20 concentrations for the
majority of patients studied, whereas hepcidin-25 re-
mained increased 7 days after the incident. The authors
concluded that hepcidin-20, rather than hepcidin-25,
may be helpful for the diagnosis of acute myocardial
infarction (14).
Several reports suggest the potential use of hepci-
din concentrations in determining cardiovascular risk.
It has been hypothesized that increased hepcidin con-
centrations may enhance cardiovascular risk by in-
creasing intracellular macrophage iron concentrations
and by increasing their atherogenic potential (186–
189). Furthermore, recent studies showed increased
hepcidin production in patients with (low-grade) in-
flammation, obesity, and nonalcoholic fatty liver dis-
ease, which are traditionally associated with cardiovas-
cular disease (21, 144, 190, 191). Additional data were
reported that suggested an atherogenic function of
hepcidin in a study that revealed that ex vivo
hepcidin-25 treatment of differentiating monocytes
from patients with the metabolic syndrome induced
monocyte chemoattractant protein-1 (192). More-
over, hepcidin concentrations in these patients were
associated with increased concentrations of monocyte
chemoattractant protein-1 and vascular damage. These
observations raise the possibility that hepcidin may
prove to be a novel determinant for cardiovascular dis-
ease risk.
Hepcidin in cancer. Patients with cancer often suffer
from anemia, generally in association with other mark-
ers of inflammation. Studies in patients with multiple
myeloma suggest that hepcidin is upregulated in these
patients by both IL-6 – dependent and IL-6 –indepen-
dent mechanisms that may play a role in the anemia
often observed in these patients. The IL-6–independent
pathway may be attributed to increased BMP-2 con-
centrations, which have been suggested to act synergis-
tically with IL-6 to induce hepatocyte hepcidin synthe-
sis (193, 194).
For Hodgkin lymphoma we recently demon-
strated that increased IL-6 production is associated
with induction of hepcidin, which contributes to the
iron-restricted anemia of chronic disease often ob-
served at Hodgkin lymphoma diagnosis. However, in
this study increased hepcidin concentrations appeared
insufficient for the development of anemia (195), sug-
gesting that compensation by increased erythropoiesis
through increased EPO production may explain the
lack of anemia in cancer despite increased hepcidin
concentrations (196).
In a study among anemic cancer patients receiving
ESA therapy, those with relatively low hepcidin con-
centrations at baseline showed a better response (197).
Surprisingly, these results are not fully consistent with
those found for patients with CKD (see above), but
suggest that baseline hepcidin concentrations may play
a potential role as a predictive marker to identify pa-
tients who either are going to respond adequately to
EPO therapy or need to be excluded from anemia cor-
rection with ESA owing to a low chance of responding.
Although the number of studies on the role of hep-
cidin in the anemia of cancer is limited, these studies
have contributed to our insights regarding the mecha-
nisms involved. Future studies are needed to assess the
position of hepcidin in clinical decision making in
these patients.
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Hepcidin in sports medicine. The prevalence of iron de-
ficiency is high among athletes. A number of exercise-
generated mechanisms may contribute to this low iron
status of athletes, including hemolysis, hematuria,
sweating, and gastrointestinal bleeding (198). Re-
cently, several (199–201) but not all (202) studies
showed increased urinary hepcidin concentrations af-
ter exercise. These findings of increased hepcidin con-
centrations led Peeling et al. to propose that exercise-
induced increases in hemolysis and hepcidin
expression may have 2 effects. First, any postexercise
free iron uptake by the RE macrophages may be
trapped within the scavenger cell owing to the action of
hepcidin on the ferroportin transporters, thereby af-
fecting the recycling of iron back into the circulation.
Second, increased hepcidin activity postexercise may
reduce the absorption of iron from the diet (203). Hep-
cidin might thus be a mediator of the high incidence of
iron deficiency among athletes.
Hepcidin-Modulating Agents
Hepcidin-targeted therapies may improve treatment
options for patients suffering from iron disorders. Al-
though no specific hepcidin therapies are available,
several compounds are under development as hepcidin
agonists or antagonists [reviewed in (204–206)]. Hep-
cidin agonists could be useful to prevent iron overload
attributed to hepcidin deficiency, such as HH, and es-
pecially -thalassemias and other iron-loading
anemias, and possibly some acquired forms of non-
hemochromatotic iron-overload diseases. Hepcidin
antagonists, on the other hand, might be expected to
benefit patients with diseases of hepcidin excess mani-
fested as iron-restricted anemia and systemic iron de-
ficiency, such as iron-refractory IDA, ACD (rheumatic
diseases, inflammatory bowel diseases, autoimmune
diseases), CKD, multiple myeloma and other cancers,
obesity-related iron deficiency, and cardiovascular
disease.
HEPCIDIN AGONISTS
Preclinical studies and some clinical studies have pro-
vided proof-of-concept for synthetic hepcidin-25,
small hepcidin peptides, BMP agonists, and HIF stabi-
lizers to prevent iron overload attributed to hepcidin
deficiency.
Small hepcidin peptides have been shown to act as
agonists in mice in vivo on the basis of their amino-
terminal domain (206). Gardenghi et al. reported that
transgenic hepcidin overexpression in -thalassemia
intermedia mice decreased iron overload, and even
ameliorated ineffective erythropoiesis (207).
Hepcidin concentrations can also be induced by
targeting the BMP pathway (Fig. 4). BMP-2 adminis-
tration in mice was found to increase liver hepcidin
expression and reduce serum iron concentrations in
vivo (208). Supraphysiological doses of exogenous
BMP-6 for 10 days also were reported to improve hep-
cidin deficiency, reduce serum iron, and redistribute
tissue iron to appropriate storage sites (RE macro-
phages, spleen) in a mouse model for HFE hemochro-
matosis (209). HIF antagonists are used in cancer to
inhibit tumor angiogenesis (210). Blocking HIF could
also be of useful for increasing hepcidin concentrations
in iron-overload diseases.
HEPCIDIN ANTAGONISTS
Preclinical and clinical studies have also shown that
hepcidin antagonists such as hepcidin antibodies, BMP
antagonists, cytokine receptor antibodies, and HIF sta-
bilizers can decrease hepcidin expression and reverse
iron abnormalities (208, 211–218).
In a proof-of-principle study, Sasu et al. neutral-
ized hepcidin by a monoclonal antibody in the Brucella
abortus mouse model of anemia of inflammation and
found it to restore responsiveness to EPO (211). The
results of this study suggest that administration of
antihepcidin therapies alone or in combination with
erythropoiesis-stimulating agents may improve pa-
tients’ erythropoietic response and allow the use of
lower EPO doses to avoid the potential detrimental ef-
fects of high EPO concentrations. Notably, monitoring
of the bioactive serum hepcidin during treatment by
these hepcidin antagonists appears to be complicated
by the interference of the compounds in the assays
(219).
Several components can interfere with the BMP/
SMAD pathway. Administration of dorsomorphin, a
small inhibitor of BMP signaling, prevented hepcidin
induction by iron in mice (212). GDF15 and TWSG1
are both BMP antagonists produced by erythroblasts
and putative components of the erythroid regulator
that can inhibit hepcidin expression in vitro. Although
the physiological relevance of GDF15 and TWSG1 re-
mains to be defined, these proteins might have thera-
peutic potential. Soluble HJV, which also acts as an
antagonist of BMP signaling, decreases hepcidin base-
line expression in mice, mobilizes RE-system (splenic)
iron stores, increases liver iron content and concur-
rently increases serum concentrations (208). Also,
heparin and heparin derivatives have recently been
shown to inhibit hepcidin expression in vitro and in
vivo by interfering with BMP signaling (218).
Anti–IL-6 –receptor antibody (tocilizumab) was
shown to suppress IL-6 –induced hepcidin production
in Castleman disease (a rare disorders with systematic
inflammation and anemia), and it improved anemia in
arthritic monkeys (214–217). Inhibitors of the key ini-
tiators of the cellular hypoxic response, such as prolyl
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hydroxylases, prevent inactivation and degradation of
HIF and as such may be effective hepcidin suppressors
and restore natural iron regulation in anemia
(220, 221).
There is an increasing demand for preclinical tools
to assess the efficacy of hepcidin-related therapies.
Therefore, the diagnostic toolbox for hepcidin peptide
measurements in animal models should be improved
and extended (75, 219, 222). Moreover, well-designed
large clinical studies addressing safety and long-term
efficacy are needed to clarify the risks and benefits of
hepcidin-targeted treatments.
Concluding Remarks
Since the discovery of hepcidin 10 years ago, multiple
studies have contributed insights into the regulation of
hepcidin and its functional properties. The first reliable
assays to quantify hepcidin in human body fluids have
recently been developed, and proof-of-principle stud-
ies in human iron disorders highlight hepcidin as a
promising novel tool in diagnostic medicine, as out-
lined in Table 2. However, the use of different assay
technologies to assess hepcidin concentrations in pa-
tients with disorders of iron metabolism makes it diffi-
cult to interpret the results of the many reported stud-
ies. For example, the accumulation of hepcidin-22 and
-20 isoforms may raise questions regarding the inter-
pretation that measured hepicidin concentrations re-
flected bioactive hepcidin-25 in studies in which cer-
tain immunoassays were used. Moreover, there is a
need for harmonization of the various assays to enable
the establishment of world-wide reference intervals
and clinical decision limits. Large and well-designed
studies exploiting harmonized assays are required to
more firmly establish the position of hepcidin in diag-
nostic medicine. Furthermore, as the field moves to-
ward the use of hepcidin-related therapies, it should be
realized that the outcome of assays that are used to
monitor the fate of hepcidin during antihepcidin ther-
apy may be affected by compounds that interfere with
hepcidin. In cases in which interference has occurred,
assays must be revalidated for this specific application
before definite conclusions on the efficacy of the ther-
apy can be drawn. In conclusion, hepcidin is a promis-
ing diagnostic tool but efforts must be undertaken to
assess the relevance of specifically measuring hepcidin-
25, to harmonize assay outcomes throughout the
world, to define clinical decision limits, and to make
assays available to clinical laboratories before hepcidin
assays can be fully included in clinical practice.
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